The primary aim of this study was to examine whether naltrexone would alter alcohol consumption and effects based on OPRM1 genotype (with asp40 naltrexone-treated individuals drinking the least) using a previously validated (O’Malley et al., 2002; Drobes et al., 2003; Anton et al., 2004) acute dosing and bar-lab paradigm in non-treatment seeking alcoholics. A secondary aim was to explore the role of DAT genetic differences on this effect (that DAT 9 VNTR carriers would respond the best to naltrexone and potentially enhance the OPM1 genetic effect).
